Tositumomab
Top View
- Open Full Page
- (INN) for Biological and Biotechnological Substances
- Bladder Cancer
- Development of Novel Anti-Cd20 Monoclonal Antibodies And
- Y90 Ibritumomab Tiuxetan and I131 Tositumomab
- Federal Register/Vol. 76, No. 5/Friday, January 7, 2011/Notices
- Radioimmunoconjugates
- BEXXAR (Tositumomab and Iodine I 131 Tositumomab) Label
- The Evolution of Antibodies Into Versatile Tumor-Targeting Agents
- Trastuzumab-DM1: a Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer Myra F
- Brentuximab Vedotin and Diffuse Large B-Cell Lymphoma
- 1112-01-Grillo-Lopez-11.6.Mm
- Antibody Therapy of Cancer
- Association Between Gvhd and Nivolumab in the FDA Adverse Event Reporting System
- Tositumomab and I-131
- Pharmacology Update 2021
- Kinase Inhibitors and Monoclonal Antibodies in Oncology: Clinical Implications
- Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine–Labeled CD30-Specific AC-10 Antibody